Nasdaq: CFRX

Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections

Lysins – a new armamentarium for the treatment of bone and joint infections?

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Exebacase in Addition to Daptomycin against MRSA

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model

Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Single center, exploratory, open-label prospective study using the minimally invasive LysinDAIR procedure (lysin administration during an arthroscopic DAIR procedure) in patients with suspected relapsing chronic coagulase-negative staphylococci (CNS) prosthetic hip infection (PHI)

Presented at IDWeek 2022, October 19, 2022

Locally Delivered Antistaphylococcal Lysins Exebacase or CF-296 is Active in Methicillin-Resistant Staphylococcus aureus Implant-associated Osteomyelitis

Lysin Exebacase Has a Low Propensity for Resistance Development and Suppresses the Emergence of Resistance to Anti-Staphylococcal Antibiotics

Lysin CF-370 exhibits a low propensity for decreased susceptibility in Gram-negative (GN) ESKAPE pathogens

Lysin CF-370 suppresses in vitro resistance in Pseudomonas aeruginosa to meropenem, tobramycin and levofloxacin

Direct lytic agents, a novel family of antimicrobial agents, have a low propensity for decreased susceptibility in Gram-negative pathogens associated with airway infection in Cystic Fibrosis

In vitro activity of exebacase against contemporary beta-haemolytic streptococci recovered from US patients with bloodstream infections

Evaluation of the broth microdilution MIC method for exebacase against 100 beta-haemolytic streptococci

Assessment of exebacase MIC reproducibility: Thirty S. aureus isolates tested at three sites using three different commercial media lots

Direct Lytic Agents (DLAs), a Novel Family of Antimicrobial Agents, Exert Potent in vitro Bactericidal Activity Against Gram-negative (GN) Pathogens Which Cause Pulmonary Infections in CF Patients, Including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans